HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported preliminary, unaudited fourth quarter and full year 2023 net product revenue...

Related Keywords

United States ,Luis Sanay ,Jeffreym Dayno ,Drug Administration ,Paragon Biosciences ,Zynerba Pharmaceuticals ,Exchange Commission ,Prnewswire Harmony Biosciences Holdings Inc ,Share Repurchase Program ,Nasdaq ,Preliminary Net Revenue ,Fourth Quarter ,Full Year ,Representing Growth ,Product Revenue Projected Between ,Common Stock Repurchase ,Fourth Quarter Bringing ,Continue Opportunistic Share Repurchases ,Biosciences Holdings ,Healthcare Conference ,Harmony President ,Product Revenue ,Strong Growth ,Net Revenue ,Idiopathic Hypersomnia ,Myotonic Dystrophy Type ,Capital Allocation ,Maximize Shareholder ,Full Prescribing Information ,Harmony Biosciences ,Plymouth Meeting ,Private Securities Litigation Reform Act ,Annual Report ,Biosciences Investor Contact ,Biosciences Media Contact ,